VA1213是一种选择性COX-2抑制剂,通过抑制EGFR,AKT和ERK1/2酸化,表现出抗瘤活性
Valerio Ciccone1, Claudia Cecchin1, Maria Frosini1
1Department of Life Sciences, University of Siena, Siena I-53100, Italy.
概括
新型循环氧化酶-2 (COX-2) 抑制剂VA1213在体外对结直肠和乳腺癌细胞表现出强大的抗瘤活性. 它诱导了细胞亡和细胞循环停止,提供了一个有前途的治疗候选人,其机制与塞莱科克西布截然不同.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 环氧基因酶-2 (COX-2) 的过度表达与各种癌症有关,使其成为关键的治疗点.
- 现有的COX-2抑制剂,如切莱科西布,已知具有非目标效应,需要开发新型药物.
- 维西纳二甲基替代的异环化合物代表了一类新的潜在的COX-2抑制剂.
研究的目的:
- 评估新型COX-2抑制剂的体外抗瘤特性和作用机制,重点关注VA1213.
- 为了比较VA1213在结肠直肠癌和乳腺癌细胞系中的疗效和细胞效应,对结肠直肠癌和乳腺癌细胞系中的赛莱科西布.
- 研究VA1213对细胞增殖,细胞亡,细胞周期,转移以及关键信号通路的影响.
主要方法:
- 在实验室中评估HT-29和MDA-MB-231细胞系中的细胞毒性,亡诱导和细胞周期分布.
- 在亚细胞毒性度下对抗转移活性,包括细胞迁移和克隆原性潜力的评估.
- 对表皮生长因子受体 (EGFR) 下游信号通路 (ERK1/2,AKT酸化) 的变化的分析.
主要成果:
- VA1213在长时间暴露后表现出强烈的,时间依赖的生长抑制,与较短时间暴露相比,IC50值较低.
- VA1213通过caspase-3激活诱导了G0/G1细胞循环停止和细胞亡,与celecoxib的快速细胞毒性作用不同.
- VA1213有效地抑制了细胞迁移并降低了克隆性潜力,同时在没有直接抑制EGFR的情况下损害了EGFR下游信号传递.
结论:
- VA1213在体外表现出相当可比的抗瘤疗效,与赛莱科西布相美,向多个与癌症相关的信号通路.
- 其独特的作用机制,包括延迟的细胞毒性和干扰EGFR信号传递,表明潜在的减少非目标效应.
- VA1213代表了癌症治疗的有前途的治疗候选者,需要进一步在体内研究疗效和安全性.
相关概念视频
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:22PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K
02:15M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K